Company: DAWN
Filing Date: 2025-06-03
Form Type: 8-K
Source: 0001193125-25-134103
Chunk: 0

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-06-03
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07.      Submission of Matters to a Vote of Security Holders.  

On June 2, 2025, Day One Biopharmaceuticals, Inc. (the “ Company”) held its 2025 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals:

  The election of two Class I Directors, Natalie Holles and Garry Nicholson, M. B. A., each to serve a three-year term, which will expire at the 2028 Annual Meeting of Stockholders and until such...  

  Nominees                       Shares For                      Shares Withheld                      Broker Non-Votes                 
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Natalie Holles                                 81,975,302                            1,357,027                            6,470,934  
  Garry Nicholson, M. B. A.                      65,553,238                           17,779,091                            6,470,934  

  The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. The vote tally wa...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Shares For      Shares Against      Shares Abstaining  
 ─────────────────────────────────────────────────────────
  89,705,033              74,951                 23,279  

  The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The vote tally was as follows:  

  Shares For      Shares Against      Shares Abstaining      Broker Non-Votes  
 ───────────────────────────────────────────────────────────────────────────────
  82,385,592             879,957                 66,780             6,470,934  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                                   DAY ONE BIOPHARMACEUTICALS, INC.                     
  Date: June 3, 2025      By:      /s/ Charles N. York II, M. B. A.                     
                                   Charles N. York II, M.